Most Read Articles
6 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
6 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

3 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.

Product Highlight - XOFLUZA

16 Sep 2020

ONE AND DONE

  •  Taken only once, Xofluza stops viral replication leading to undetectable levels of virus* within 24 hours** and provides patients with flu relief within 2-3 days^,1,2
  •  Xofluza the first-in-class influenza antiviral in 20 years with a novel mode of action3

* Infectious virus

**In otherwise healthy patients with influenza in the CAPSTONE-1 study, Xofluza demonstrated a median time to cessation of viral shedding of 24 hours vs. 96 hours with placebo and 72 hours with oseltamivir (p<0.001 vs. both placebo and oseltamivir)

^Median time to alleviation of symptoms was 54 hours (2.3 days) with Xofluza compared with 80 hours (3.3 days) with placebo (p<0.001), in otherwise healthy patients with influenza in the CAPSTONE-1 study. 



References:
1. Hayden FG et al. N Engl J Med 2018; 379: 913–923.
2. Xofluza Prescribing Information, Malaysia. MYXofluza20200520CDS7.1
3. Noshi T el al. Antiviral Res 2018; 160: 109-117.


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
6 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

3 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.